Therapy Management of PARP Inhibitor Combinations in mCRPC Clinical Practice
Abstract
Innovative therapeutic approaches, including poly(ADP-ribose)polymerase inhibitors (PARPi), have shown promising results in metastatic castration-resistant prostate cancer (mCRPC), particularly when combined with androgen receptor inhibitors (ARPi). Irrespective of HRR gene mutations, patients benefit from improved radiological progression-free survival and overall survival. The success of PARPi/ARPi combination therapy relies heavily on the effective management of both treatment administration and the associated side-effects. Common haematological side-effects include anaemia, leukopenia, and thrombocytopenia, whereas non-haematological reactions - particularly fatigue, diarrhea, nausea, and constipation - are also clinically relevant. In addition to basic diagnostics and preventive measures, dose adjustments or temporary discontinuation may be required depending on the severity of the side-effects. For anaemia, the most common side-effect, supportive measures such as blood transfusions may be necessary to ensure optimal patient care. This guide provides uro-oncologists with practical recommendations for daily clinical practice.
Innovative Therapieansätze wie die Poly-(ADP-Ribose)-Polymerase-Inhibitoren (PARPi) haben beim metastasierten kastrationsresistenten Prostatakarzinom (mCRPC), insbesondere in Kombination mit Androgenrezeptorblockern (ARPi), vielversprechende Ergebnisse gezeigt. Patienten profitieren – unabhängig von HRR-Genmutationen – von verbesserten…
Read the paper
Related studies
- Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents
- On model selections for repeated measurement data in clinical studies
- Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells
- Region-specific microRNA signatures in the human epididymis
- Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
- In Vitro characterization of the endocrine disrupting effects of per- and poly-fluoroalkyl substances (PFASs) on the human androgen receptor
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.